Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases—past, present and future. Nat Rev Rheumatol. 2017;13:443–8.
Article CAS PubMed Google Scholar
Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol [Internet]. Frontiers; 2021 [cited 2021 Jul 19];0. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fphar.2021.621247/full
Bandoli G, Singh N, Strouse J, Baer RJ, Donovan BM, Feuer SK, et al. Mediation of adverse pregnancy outcomes in autoimmune conditions by pregnancy complications: a mediation analysis of autoimmune conditions and adverse pregnancy outcomes. Arthritis Care Res. 2020;72:256–64.
Somers EC. Pregnancy and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2020;64:3–10.
Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. Am J Clin Dermatol [Internet]. 2022 [cited 2022 May 3]; Available from: https://doi.org/10.1007/s40257-022-00679-y
Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43:910–23.
Article CAS PubMed PubMed Central Google Scholar
Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996;26:1527–31.
Article CAS PubMed Google Scholar
Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36:248–55.
Article CAS PubMed Google Scholar
Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo R-M, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228–33.
Article CAS PubMed Google Scholar
Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7–12.
Article CAS PubMed Google Scholar
Cavadino A, Sandberg L, Öhman I, Bergvall T, Star K, Dolk H, et al. Signal detection in EUROmediCAT: identification and evaluation of medication-congenital anomaly associations and use of vigibase as a complementary source of reference. Drug Saf. 2021;44:765–85.
Article CAS PubMed Google Scholar
Trifirò G, Isgrò V, Ingrasciotta Y, Ientile V, L’Abbate L, Foti SS, et al. Large-scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an italian distributed multi-database healthcare network: the VALORE project. BioDrugs. 2021;35:749–64.
Article PubMed PubMed Central Google Scholar
Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res. 2020;72:461–88.
Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Gastroenterology. 2019;156:1508–24.
Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–92.
Article CAS PubMed Google Scholar
Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110–9.
Article CAS PubMed Google Scholar
Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951–8.
Article CAS PubMed Google Scholar
Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol. 2012;41:196–201.
Article CAS PubMed Google Scholar
Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727–39.
Article CAS PubMed PubMed Central Google Scholar
Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol Elmsford N. 2014;43:78–84.
PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy [Internet]. Epistemonikos. [cited 2022 Sep 22]. Available from: https://www.epistemonikos.org/en/documents/74ab54ddb26493ee5d6490b16f6a2a2b87532d24
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREATTM registry. Am J Gastroenterol. 2012;107:1409–22.
Article CAS PubMed PubMed Central Google Scholar
Ghalandari N, Kemper E, Crijns IH, Wolbink G, Rispens T, Smeele HT, et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis. 2022;81:402–5.
Article CAS PubMed Google Scholar
Clowse M, Fischer-Betz R, Nelson-Piercy C, Scheuerle AE, Stephan B, Dubinsky M, et al. Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol. Ther Adv Musculoskelet Dis. 2022;14:1759.
Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION). Am J Gastroenterol. 2018;113:1669–77.
Article CAS PubMed Google Scholar
Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113:396–403.
Article CAS PubMed Google Scholar
Perrotta K, Kiernan E, Bandoli G, Manaster R, Chambers C. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series. Rheumatol Adv Pract. 2021;5:74.
Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 2013;32:695–700.
Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42:409–19.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–17.
Article CAS PubMed Google Scholar
Standardised MedDRA Queries [Internet]. [cited 2022 Sep 25]. Available from: https://www.meddra.org/standardised-meddra-queries
Vigibase [Internet]. Available from: https://www.who-umc.org/vigibase/vigibase/
Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519–23.
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905–8.
Article CAS PubMed PubMed Central Google Scholar
Roux E, Thiessard F, Fourrier A, Bégaud B, Tubert-Bitter P. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed Publ IEEE Eng Med Biol Soc. 2005;9:518–27.
Gelder MM, Jong Berg LTW, Roeleveld N. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks. Hum Reprod Oxf Engl. 2014;29:168–83.
Odufalu F-D, Long M, Lin K, Mahadevan U. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut. 2022;71:1766–72.
Palmsten K, Bandoli G, Vazquez-Benitez G, Xi M, Johnson DL, Xu R, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatol Oxf Engl. 2020;59:1262–71.
Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017;15:95.
Article PubMed PubMed Central Google Scholar
Shields KE, Lyerly AD. Exclusion of pregnant women from industry-sponsored clinical trials. Obstet Gynecol. 2013;122:1077–81.
留言 (0)